MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

A.R. Chakraborty, R.W. Robey, V.L. Luchenko, Z. Zhan, R.L. Piekarz, J.P. Gillet, A.V. Kossenkov, J. Wilkerson, L.C. Showe, M.M. Gottesman, N.L. Collie, S.E. Bates

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.'. Together they form a unique fingerprint.

Medicine and Dentistry